Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company focused on developing therapies to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The update emphasizes the company's lead programs and recent financial developments.
NeOnc's lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy for most brain cancer patients. NEO212 is designed to address key limitations of current treatment, including BBB penetration and MGMT-driven resistance. The Phase 1 dose escalation study in recurrent glioblastoma (GBM) has completed, establishing a Recommended Phase 2 Dose of 610 mg and showing early signs of disease control. This positions the program to advance into Phase 2 efficacy evaluation.
Another key program is NEO100, an intranasal therapy for recurrent GBM. Phase 2 data have shown radiographic responses and improved progression-free survival compared to historical salvage benchmarks. NeOnc's platform approach combines intranasal and oral drug delivery technologies to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications.
Financially, NeOnc recently completed a successful PIPE offering, adding $16.0 million gross to the company's balance sheet. This capital infusion is expected to support the advancement of its clinical programs.
The full announcement, including downloadable images and bios, is available here. Stonegate Capital Partners is a capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services.
For more information, contact Stonegate Capital Partners at (214) 987-4121 or visit their website. The press release was distributed by Reportable, Inc.
